

Molecular Surveillance of *Pfkelch13* and *Pfmdr1* Mutations in *Plasmodium falciparum* Isolates from Southern Thailand

Thunchanok Khammanee¹, Nongyao Sawangjaeroen¹, Hansuk Buncherd², Aung Win Tun³,
Supinya Thanapongpichat^{2,*}

¹Department of Microbiology, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, Thailand; ²Faculty of Medical Technology, Prince of Songkla University, Hat Yai, Songkhla, Thailand; ³Faculty of Graduate Studies, Mahidol University, Salaya, Nakhon Pathom, Thailand

Abstract: Artemisinin-based combination therapy (ACT) resistance is widespread throughout the Greater Mekong Subregion. This raises concern over the antimalarial treatment in Thailand since it shares borders with Cambodia, Laos, and Myanmar where high ACT failure rates were reported. It is crucial to have information about the spread of ACT resistance for efficient planning and treatment. This study was to identify the molecular markers for antimalarial drug resistance: *Pfkelch13* and *Pfmdr1* mutations from 5 provinces of southern Thailand, from 2012 to 2017, of which 2 provinces on the Thai-Myanmar border (Chumphon and Ranong), one on Thai-Malaysia border (Yala) and 2 from non-border provinces (Phang Nga and Surat Thani). The results showed that C580Y mutation of *Pfkelch13* was found mainly in the province on the Thai-Myanmar border. No mutations in the *Pfkelch13* gene were found in Surat Thani and Yala. The *Pfmdr1* gene isolated from the Thai-Malaysia border was a different pattern from those found in other areas (100% N86Y) whereas wild type strain was present in Phang Nga. Our study indicated that the molecular markers of artemisinin resistance were spread in the provinces bordering along the Thai-Myanmar, and the pattern of *Pfmdr1* mutations from the areas along the international border of Thailand differed from those of the non-border provinces. The information of the molecular markers from this study highlighted the recent spread of artemisinin resistant parasites from the endemic area, and the data will be useful for optimizing antimalarial treatment based on regional differences.

Key words: *Pfkelch13*, *Pfmdr1*, artemisinin resistance, Southern Thailand

INTRODUCTION

Malaria remains a leading health problem in many countries, particularly those in tropical and subtropical regions of the world [1]. The countries of Greater Mekong Subregion (GMS) (i.e., Thailand, Cambodia, Laos, Myanmar, Vietnam, and China) have developed resistance to antimalarial drugs [2] although they set the target to eliminate malaria by 2030 [3]. In the late 1950s, the chloroquine resistance was initially reported in the Cambodia-Thailand border. It was then followed by the resistance to sulfadoxine-pyrimethamine, mefloquine and quinine [4]. Artemisinin-based combination therapy (ACT), either with mefloquine, lumefantrine, or piperazine, is adopted as the main line of treatment for uncompli-

cated falciparum malaria [5]. The artemisinin kills the asexual blood stage of the parasites and it rapidly clears parasites than any other antimalarial drugs could do [6,7], while the partner drug eliminates the remaining parasites [8]. However, in 2006, the first observed reduction of parasites clearance was detected in patients from western Cambodia after an artemisinin therapy [9]. These cases confirmed that the artemisinin resistance had occurred along the Cambodia-Thailand border, the same area where chloroquine resistance was observed several decades ago [5,10]. Recently, the artemisinin resistance has already spread to 5 countries of the GMS [11]. Unfortunately, there is a simultaneous emergence of partner drug resistance, including resistance to artemether-lumefantrine, artesunate-amodiaquine, artesunate-mefloquine and artesunate-sulfadoxine-pyrimethamine, resulting in high treatment failure rate along Cambodian-Thai, Cambodia-Laos, and Thai-Myanmar borders [12].

Mutations in *Pfkelch13* propeller region were usually associated with artemisinin-resistance [13] and the highly frequent mutations detected in the eastern GMS (Cambodia, Lao PDR,

•Received 12 November 2018, revised 6 June 2019, accepted 15 July 2019.

*Corresponding author (supinya.th@psu.ac.th)

© 2019, Korean Society for Parasitology and Tropical Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

and Viet Nam) were C580Y, R539T, Y493H, and I543T. On the other hand, F446L, N458Y, P574L, and R561H mutations were common in the western GMS (China, Myanmar, and Thailand) [14]. Non-synonymous (NS) mutations in *PfKelch13* gene such as Y493H, R539T, I543T, and C580Y are the established molecular markers for artemisinin resistance in *P. falciparum* [15]. The C580Y mutation was common in western Cambodia, north-eastern Thailand, and southern Laos. Mutations in *P. falciparum* multidrug resistance gene (*Pfmdr1*) caused different in vivo efficacy and in vitro *P. falciparum* susceptibility to ACT including amodiaquine [16,17], mefloquine [18,19], lumefantrine [20,21] and artemisinin derivatives [19]. It was suggested that changes in sequence or copy number of *Pfmdr1* altered influx and efflux of several drugs in the parasite food vacuole [22]. The 5 common genotypes of *Pfmdr1* were N86Y, Y184F, S1034C, N1042D, and D1246Y. *Pfmdr1* N86Y mutation was associated with chloroquine and amodiaquine resistance [2-4], while Y184F mutation was common with increased resistance to mefloquine and artesunate [23]. Point mutations at S1034C, N1042D, and D1246Y have been reported as resistance to quinine and increased susceptibility to mefloquine, halofantrine, and artemisinin derivatives [19,24,25].

Southern Thailand consists of 14 provinces with a population of about 8.7 million. It is in borders with Malaysia to the south and Myanmar to its upper west. In Malaysia, the incidence of malaria is estimated to be 13 cases per 100,000 populations [26] and the prevalence of antimalarial drug resistance was relatively low [27]. The molecular analysis showed a single copy of *Pfmdr1* and wild-type *PfKelch13* genes indicating that Malaysia has limited case of artemisinin resistance. However, the prevalence of malaria is higher in southern Thailand especially in areas bordering with the countries such as Myanmar. The dramatic increase of malaria cases in southern Thailand is attributed to its tropical rainforest, relatively higher proportion of migrant workers for rubber plantations from neighboring countries, and the prolonged insurgency in some provinces [4].

The aim of the present study is to analyze the molecular markers associated with *P. falciparum* resistance to antimalarial drugs in the *Kelch13* and *Pfmdr1* genes from the samples collected from Southern Thailand. The results would provide crucial evidence for further molecular surveillance of ACT in this part of the world. The information from this study can be used for efficient planning and targeting of malaria control in southern Thailand.

MATERIALS AND METHODS

Blood collection

The dried blood spots samples were received from the Office of Disease Prevention and Control 11 and 12, Thailand. The samples were collected from uncomplicated falciparum malaria patients when they attended their first visit to the malaria clinic and were positive on microscopic examination, but they did not have prior antimalarial treatment. Neither treatment outcome nor parasite clearance was followed up. The blood samples were obtained by finger-prick and spotted on filter paper (Whatman 3MM, GE Healthcare, Buckinghamshire, UK) for approximately 80 µl. Individual samples were stored in each plastic bag at room temperature before DNA extraction. DNA was extracted using QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Genomic DNA was eluted into 100 µl of elution buffer and used immediately or stored at -20°C until use.

Ethical approval for this study was obtained from the Faculty of Medicine, Prince of Songkla University (REC60-096-19-2).

Detection of *PfKelch13* propeller gene

The presence of *P. falciparum* was confirmed in all samples by nested PCR with species-specific primers based on 18S rRNA gene, as described by Snounou et al. [28]. *P. falciparum kelch13* was amplified from the genomic DNA using nested PCR following the protocol previously described by Ariey et al. [13] with some modifications. In the first PCR, the full-length *Pfkelch13* gene sequence (1-2,283 bp) was amplified with a primer pair K13-1F (5'-TGGAAGGAGAAAAAGTAAAAACAAA-3') and K13-2283R (5'-TGTGCATGAAAATAAATATTAAGAAG-3'). The PCR product was then amplified into 3 fragments in the second PCR step. The length of fragment 1 was 718 bp using K13-1F (see above) and K13c694-R (5'-TCTCGAATAAAATTCATTTGTGCTT-3'). The fragment 2 covered positions 621-1538 using the primers K13c621F (5'-CGGAATTAAGTGATGCTAGTGA-3') and K13c1538R (5'-CGATCATAACCTCAGTTTCAA-3') to produce 917 bp product. The third fragment was amplified at the nucleotide positions 1344-2129 with the primer pairs K13c1344F (5'-AGGTGGATTGATGGTGTAGAA-3') and K13c2129R (5'-GGGC-CAAGCTGCCAATTCATTCATTTGT-3') to produce amplicons of 786 bp. In each PCR reaction, 5 µl of genomic DNA was amplified in 25 µl of PCR master mix using 2 mM MgCl₂ for first round PCR and 3 mM MgCl₂ for second round PCR, 250 µM of dNTPs, 250 nM of oligonucleotide primers, 0.5 units of Platinum *Taq*

DNA polymerase (Invitrogen, Carlsbad, California, USA), and 3 µl of PCR product from the first PCR for the second PCR. The first PCR was performed with an initial denaturation at 94°C for 5 min, 30 cycles of denaturation at 94°C for 1 min, annealing at 58°C for 2 min, extension at 72°C for 2 min and the final extension at 72°C for 10 min. The second PCR was done with 35 cycles of denaturation at 94°C for 1 min, annealing for 2 min at 55°C for fragment 1 and 58°C for fragment 2, extension at 72°C for 2 min, and the final extension at 72°C for 5 min. The PCR products were analyzed on a 2% agarose gel electrophoresis stained with 0.5 µg/ml ethidium bromide and visualized under UV light.

Detection of *Pfmdr1* gene

Five mutations of the *Pfmdr1* gene were amplified using the 2 primer pairs as described in the previous study [29]. The sequences of codons 86 and 184 were amplified with primer pairs MDR1F (5'-AGAGAAAAAGATGGTAACCTCAG-3') and MDR1R (5'-ACCACAAACATAAATTAACGG-3') with an expected amplified amplicons length of 590 bp. The second amplicon was amplified with the primer pairs MDR2F (5'-GCGGAGTTTTTCATTTAGTTCAGATGATG-3') and MDR2R (5'-AGCAGCAAACCTACTAACACGTTTAACATC-3') to have the fragment length of 968 bp which contained the sequences of codons 1034, 1042, and 1246. The total reaction mixture of 25 µl consisted 1× PCR buffer, 3 mM MgCl₂, 0.2 mM of each deoxynucleotide triphosphate (dNTP), 0.2 µM of each oligonucleotide primers, 0.5 units of Platinum *Taq* polymerase and 5 µl of DNA template. The target amplification of MDR1 was programmed for initial denaturation at 95°C for 5 min, 35 cycles of 95°C for 1 min, 55°C for 1.30 min, 72°C for 2 min and final extension at 72°C for 8 min. For MDR2F/R, the conditions were an initial denaturation at 95°C for 3 min followed by 35 cycles of 93°C for 30 sec, 53°C for 30 sec, 72°C for 1 min and final extension at 72°C for 5 min. The PCR products were evaluated by electrophoresis on a 1.5% agarose gel and visualized with ethidium bromide staining.

Sequence analysis

The PCR products of *PfKelch13* and *Pfmdr1* amplicons were cleaned using QIAquick PCR purification kit (Qiagen) before sequencing by ABI Sequencer (Macrogen, Seoul, Korea). DNA sequences were aligned using BioEdit v7.2.5 with the reference sequences PF3D7_1343700 for *PfKelch13* and PF3D7_0523000 for *Pfmdr1* respectively.

PCR or sequencing was repeated if the amplification was

unsuccessful, or the sequence chromatogram was vague at some point. In addition, some of the samples were repeated for sequencing to confirm the result. Data analysis was performed using Microsoft Excel 2007 and analyzed by SPSS 19.0 (SPSS Inc., Chicago, Illinois, USA).

RESULTS

A total of 128 uncomplicated falciparum malaria samples were obtained from 5 provinces of Southern Thailand (Fig. 1) from 2012 to 2017. All the samples were divided into 2 groups according to their geographical locations. The first group was from the 3 provinces that shared a border with the neighboring countries of Thailand and the second group was from the 2 provinces which were not located at the Thai border. The first group consisted of 16 samples from Chumphon (10 samples in 2013, 6 samples in 2014), 40 samples from Ranong (8 samples in 2012, 13 samples in 2013, 19 samples in 2015) and 12 samples from Yala in 2017 respectively. Chumphon and Ranong provinces are located at the Thai-Myanmar border while Yala shares border with Malaysia. The second group had 60 samples which were from Phang Nga and Surat Thani provinces and comprised of 14 samples from Phang Nga (4 samples in 2012, 10 samples in 2015), and 46 samples from Surat Thani (17 samples in 2014, 19 samples in 2015, 10 samples in 2016). Table 1 summarises the molecular analysis of *PfKelch13* and *Pfmdr1* genes together with the respective year of sample collection.

PfKelch13 mutations

In this study, artemisinin resistance-confirmed mutations, C580Y and P574L were identified in provinces located at Thai-Myanmar border, Chumphon and Ranong, and in one non-border province, Phang Nga. C580Y mutation was detected in 13 of 40 samples (32.5%) from Ranong: 1 of 8 samples (12.5%) in 2012 and 6 of 13 samples (46.15%) in 2013 and 6 of 19 samples (31.58%) in 2014, respectively. It is interesting to note that the samples from Phang Nga, only 230 km south of Ranong, showed C580Y mutation in 2 of 10 samples (20%) in 2015. Chumphon province had P574L mutation in 1 of 6 samples (16.67%) in 2014, and 10 samples received in 2013 had no *PfKelch13* mutation. Two samples had more than one mutations in *PfKelch13* gene from the samples of the same year 2012. Of these, one isolate from Ranong had the mutation at N554S/I590T, and the other isolate (1 of 4 samples)




Fig. 1. Geographic distribution of *P. falciparum* *Kelch13* and *Pfmdr1* mutations collected in 5 provinces of Southern Thailand including 2 provinces on the Thai-Myanmar border (Chumphon and Ranong), 2 from non-border provinces (Surat Thani and Phang Nga) and 1 from Thai-Malaysia border (Yala). Pie charts show the percentages of the mutations in 2 genes observed among 128 parasite samples collected between 2012 and 2017.

Table 1. Summary of *PfKelch13* and *Pfmdr1* mutations identified in 5 southern provinces of Thailand together with the year of sample collection

Parasite isolates	Year	<i>PfKelch13</i> Amino acid position					<i>Pfmdr1</i> Amino acid position				
		wild-type (%)	H366L*+C447Y*+V510G* (%)	N554S+I590T* (%)	P574L (%)	C580Y (%)	wild-type (%)	N86Y (%)	E130K (%)	Y184F (%)	Y184F+N1042D (%)
Chumphon	2013 (n=10)	10 (100)	-	-	-	-	8 (80)	2 (20)	-	-	-
	2014 (n=6)	5 (83.3)	-	-	1 (16.67)	-	3 (50)	2 (33.33)	1 (16.67)	-	-
Ranong	2012 (n=8)	6 (75)	-	1 (12.5)	-	1 (12.5)	8 (100)	-	-	-	
	2013 (n=13)	7 (53.85)	-	-	-	6 (46.15)	9 (69.23)	3 (23.08)	-	1 (7.69)	
	2015 (n=19)	13 (68.42)	-	-	-	6 (31.58)	16 (84.21)	1 (5.26)	-	2 (10.53)	
Phang Nga	2012 (n=4)	3 (75)	1 (25)	-	-	-	4 (100)	-	-	-	
	2015 (n=10)	8 (80)	-	-	-	2 (20)	10 (100)	-	-	-	
Surat Thani	2014 (n=17)	17 (100)	-	-	-	-	7 (41.18)	7 (41.18)	-	3 (17.64)	
	2015 (n=19)	19 (100)	-	-	-	-	7 (36.84)	4 (21.05)	-	5 (26.32)	
	2016 (n=10)	10 (100)	-	-	-	-	-	7 (70)	-	2 (20)	
Yala	2017 (n=12)	12 (100)	-	-	-	-	-	12 (100)	-	-	
Total	128	110	1	1	1	15	72	38	1	13	

*Novel mutation.

Chumphon, n=16; Ranong, n=40; Phang Nga, n=14; Surat Thani, n=46; Yala, n=12.

from Phang Nga had H366L+C447Y+V510G, the 3 mutations present in a single sample which had not been detected elsewhere. Of these mutations, N554S has been reported from Mali in 2011 [30] and Ungoye, Kenya, in 2012 [31]. Unlike the mutation of *PfKelch13* presented on Thai-Myanmar border, *P. falciparum* circulated in Thai-Malaysia border, Yala in 2017, had 100% wild-type on *PfKelch13* polymorphism. Forty-six

isolates in 2014-2016 from Surat Thani, the non-border province had no evidence of molecular markers associated with artemisinin resistance.

***Pfmdr1* mutations**

Out of 128 samples, 72 samples (56.25%) showed the *Pfmdr1* wild-type while 38 samples (29.69%) had N86Y muta-

tion. Less frequently, E130K was observed in 1 (0.78%), Y184F in 13 (10.16%), and Y184F plus N1042D in 4 (3.12%) samples respectively. However, mutations at S1034C and D1246Y were not identified in the present study. Two provinces along the Thai Myanmar border, Chumphon and Ranong had the N86Y mutation in 20% (2/10 samples) in 2013, 33.33% (2/6 samples) in 2014, 23.08% (3/13 samples) in 2013, and 5.26% (1/19 samples) in 2015, respectively whereas *Pfmdr1* Y184F mutation was detected in 7.69% (1/13 samples) in 2013 and 10.53% (2/19 samples) in 2015, but this mutation was not found in Chumphon. E130K was found in one isolated from Chumphon in 2014. This study was the first report of *Pfmdr1* isolated from parasites in Surat Thani province. The N86Y mutation was observed in 7/17 samples (41.18%) in 2014, 4/19 samples (21.05%) in 2015 and 7/10 samples (70%) in 2016 respectively. For Y184F mutation, it was detected for 17.6% in 2014 (3/17 samples), 26.3% in 2015 (5/19 samples) and 20% in 2016 (2/10 samples) respectively. Double mutant genotypes Y184F plus N1042D appeared in the present study for 15.7% in 2015 (3/19 samples) and 10% in 2016 (1/10 samples). No mutations on *Pfmdr1* gene associated with multidrug resistance were identified in the parasites isolated from Phang Nga province. However, in Yala province (Thai-Malaysia border), the point mutation N86Y in *Pfmdr1* was present in 100% of the isolates.

DISCUSSION

Several studies have reported the mutations conferring drug resistance was commonly present in the area such as Thai-Cambodian, Thai-Myanmar and Thai-Laos borders. Drug resistance in malaria is frequently checked using molecular markers such as *PfKelch13* gene for Artemisinin resistance, and *P. falciparum* multidrug resistance1 gene, for the partner drugs resistance such as chloroquine mefloquine, lumefantrine and quinine [32]. Since the last decade, the increasing prevalence of confirmed mutations for artemisinin resistance in *PfKelch13* have been reported along the Thai-Cambodia and Thai-Myanmar borders, and in the GMS region [13,14,33-35]. The people with subclinical infection carrying the resistant *P. falciparum* allele might contribute to the spread of artemisinin-resistant gene to Thailand via cross-border movements. Mae Hong Son, one of the northwestern provinces, and Surat Thani and Yala provinces in southern Thailand have limited artemisinin-resistant genes [36] even though they are in the endemic

area and are mainly rural, forested and bordering with Myanmar. Hence, it is crucial to monitor the current status of artemisinin resistance in the region using molecular markers as well as therapeutic efficacy, especially in an area where we have limited knowledge for *P. falciparum* drug resistance.

Since 2009, the first-line treatment for uncomplicated *P. falciparum* infections had been changed from 2-days artesunate-plus-mefloquine to 3-days regimen in eastern and western Thailand [5,15,37]. However, widespread mefloquine resistance has been reported in Thailand because it was used as monotherapy over the last few decades. Data from the present study revealed the *PfKelch13* and *Pfmdr1* mutations from 5 Thailand provinces, collected from 2012 to 2017. We divided the sample into 2 groups: the first group contains samples from the 3 provinces bordering with 2 countries and the second group from the 2 provinces that do not share a border with any other country. The prevalence of *PfKelch13* artemisinin resistance-confirmed mutations, C580Y mutation, mainly found in the provinces located at Thailand-Myanmar border, especially in Ranong, was compared with other sites in this study. The result was consistent with the previous studies [36,38]. Phang Nga, the neighboring province of Ranong, had C580Y mutation in samples collected in 2015. However, the previous study by Putapornitip et al. [39] has reported that *Kelch13* mutation in *P. falciparum* collected in Phang Na at 2009 was wild type. Our result suggested that the spread of artemisinin-resistance in Phang Nga province might be due to the cross-border movements, and mobile populations of people who involved in forest-related activities from Ranong province.

Recently, the study by Kobasa et al. [36] has found that *P. falciparum* carrying C580Y mutation was present in the samples collected from Chumphon (Thailand-Myanmar border) in 2007. The present study found that P574L mutation, another confirmed mutation for artemisinin resistance [40], was found in Chumphon province in samples from 2014. This mutation was highly prevalent in neighboring countries such as Myanmar and China [41]. In contrast, there was no evidence of *PfKelch13* resistance-confirmed mutations in samples from Yala (2017), which is located at the Thailand-Malaysia border. This result was concordant with the previous report in 2015 [40]. In addition, the parasite isolates from Surat Thani, the non-border province also had no mutations in *PfKelch13* gene. Our study also indicated that no molecular markers confirmed for artemisinin resistance were detected in Surat Thani and Yala provinces.

Table 2. Comparison of molecular surveillance on artemisinin resistance and multidrug resistance of *Plasmodium falciparum* between the present studies and other studies

Mutation	Present study (Southern Thailand)	Mungthin et al. 2014 [43] (Southern Thailand)	Imwong et al. 2015 [42] (Ubon Ratchathani)	Kobasa et al. 2018 [36] (Thailand)
	2012-2017	2009	2014	2012-2018
<i>PfKelch13</i> gene				
No. of sample	128	ND	88	277
Wild-type (%)	110 (85.94)	ND	6 (6.82)	121 (43.68)
H366L+C447Y+V510G* (%)	1 (0.78)	ND	-	-
N458Y (%)	-	ND	-	3 (1.08)
R539T (%)	-	ND	17 (19.32)	6
N554S+I590T (%)	1 (0.78)	ND	-	-
P574L (%)	1 (0.78)	ND	-	-
C580Y (%)	15 (11.72)	ND	65 (73.86)	107 (38.63)
R561H (%)	-	ND	-	10 (3.61)
Other mutations (%)	-	ND	-	30 (10.83)
<i>Pfmdr1</i> gene				
No. of sample	128	558	47	ND
Wild-type (%)	69 (53.9)	-	8 (17.02)	ND
N86Y (%)	38 (29.7)	498 (89.25)	-	ND
E130K (%)	1 (0.8)	-	-	ND
Y184F (%)	13 (10.2)	58 (10.39)	39 (82.98)	ND
S1034C	-	2 (0.36)	-	ND
N1042D	-	-	-	ND
I246Y	-	-	-	ND
Y184F+N1042D (%)	4 (3.1)	-	-	ND

ND, Not determined.

Table 2 describes the comparison of different patterns of molecular markers for artemisinin resistance and multidrug resistance between the present study and the other studies. In general, the predominant genotype of *P. falciparum* isolates in Southern Thailand is the wild type for *PfKelch13* gene (85.94%) except for those from Ranong province (11.72%), the province located on Thai-Myanmar border. The recent study indicates the higher percentage of C580Y mutation (38.63%) [36] in the eastern part of Thailand such as Sisaket and Ubon Ratchathani [42] which are close to Cambodia and, Kanchanaburi and Ranong which are at Myanmar border. This implies that the artemisinin-resistant C580Y of *P. falciparum* was distributed differently between the Myanmar-Thailand and Cambodia-Thailand border regions, with southern Thailand.

Since 2015, the first-line treatment for uncomplicated *P. falciparum* infections in Thailand had been dihydroartemisinin combined with piperazine (DHA-PQ) [40] which can replace artesunate-mefloquine treatment. However, in vitro and in vivo resistance to mefloquine was highly correlated with the higher copy number of *Pfmdr1*. The mean copy number of *Pfmdr1* in the lower southern region, Yala, was 1.2 while in

Ranang, bordering with Myanmar was 2.3 [43]. The distribution of polymorphisms in our study demonstrated that *Pfmdr1* isolated from Yala province showed a single pattern N86Y mutation. The samples from Ranong in 2013 and 2014 had the mutations N86Y and Y184F respectively. These results were similar to the results of previous studies by Pickard et al. [23] and Mungthin et al. [43]. *Pfmdr1* isolated from Chumphon province in 2014 had only E130K mutation. This mutation was previously recorded in the Cambodia-Vietnam [44] and Thai-Myanmar borders [45]. In Surat Thani province, the mutation of the *Pfmdr1* gene was found at N86Y, Y184F, and Y184F plus N1042D positions. Our report would be the first report of mutation profile of *Pfmdr1* gene from Surat Thani province. The pattern of *Pfmdr1* gene mutations of *P. falciparum* were similar to the previous study by Mungthin et al. [43], showing that the frequency of N86Y were higher than those of Y184F mutation. In contrast the parasites from east of Thailand carried higher frequency of Y184F [42] (Table 2). However, in the present study, the parasites, isolates of the *Pfmdr1* gene were wild type strain distributing in all provinces except for Yala province (N86Y, 100%).

Recently, N86Y and N1042N, SNPs in the *Pfmdr1*, exhibited a significant reduction of in vitro piperazine sensitivity while copy number of *Pfmdr1* mutations had no effect on piperazine susceptibility [46]. According to our findings, the pattern of *Pfmdr1* isolates from southern Thailand would be mefloquine sensitive but resistant to chloroquine, and those parasites containing the *Pfmdr1* N86Y allele would exhibit significant reduction of piperazine sensitivity. Most parasitic strains isolated from the present study showed the *Pfmdr1* N86Y and Y184F mutation from Ranong and Surat Thani were different from those circulated in Ubon Ratchathani, which shares borders with Southern Laos and Northern Cambodia [42] suggesting that the *Pfmdr1* mutations isolated from different areas in Thailand carried the different patterns. Hence, both in vivo and in vitro efficacy studies for antimalarial drug monitoring should be done with the samples from different parts of Thailand.

In summary, the genotyping data in *Kleish13* gene collected from southern Thailand during 2012-2017 indicated that Ranong province might be responsible for the spread of the mutant allele to other areas of the southern Thailand with human movement. This result is supported by the data that approximately half of the malaria cases in Thailand were found in foreign migrant workers, and Ranong province harbors a substantial population of migrant workers in Thailand. This study reported for the first time that C580Y mutation was found in Phang Nga among the samples from 2015. This would be the recent spread of artemisinin resistance allele from Ranong province which has a high frequency of C580Y mutation. The result of SNP patterns in *Pfmdr1* is helpful for researchers to monitor changes in parasite genotypes after a change in the treatment regimen. In addition, this data will also provide information for selection of anti-malarial drug policy in Thailand; new candidate drugs should be adopted at least based on the genotype of the parasites in different areas of Thailand.

ACKNOWLEDGMENTS

This work was supported by a grant from Prince of Songkla University, contract no. MET600576S, and the Faculty of Science Research Fund, Prince of Songkla University, contract no. 1-2558-02-008.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. World Health Organization. World Malaria Report 2015 [Internet]; [cited 2018 Aug 2]; Available from: <http://www.who.int/malaria/publications/world-malaria-report-2015/en/>.
2. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. *Emerg Infect Dis* 2008; 14: 716-719.
3. World Health Organization. Strategy for malaria elimination in the Greater Mekong Subregion: 2015-2030 [Internet]; [cited 2018 Aug 3]. Available from: <http://iris.wpro.who.int/handle/10665.1/10945>.
4. USAID. President's Malaria Initiative Greater Mekong Subregion: Malaria Operational Plan FY 2017 [Internet]; [cited 2018 Aug 3]. Available from: <https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy17/fy-2017-greater-mekong-subregion-malaria-operational-plan.pdf?sfvrsn=12>.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindergardh N, Socheat D, White NJ. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 2009; 361: 455-467.
6. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. *Lancet* 2005; 366: 717-725.
7. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, Bojang K, Olaosebikan R, Anunobi N, Maitland K, Kivaya E, Agbenyega T, Nguah SB, Evans J, Gesase S, Kahabuka C, Mtove G, Nadjm B, Deen J, Mwanga-Amumpaire J, Nansumba M, Karema C, Umulisa N, Uwimana A, Mokuolu OA, Adedoyin OT, Johnson WB, Tshefu AK, Onyamboko MA, Sakulthaew T, Ngum WP, Silamut K, Stepniewska K, Woodrow CJ, Bethell D, Wills B, Oneko M, Peto TE, von Seidlein L, Day NP, White NJ. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet* 2010; 376: 1647-1657.
8. White N. Antimalarial drug resistance and combination chemotherapy. *Philos Trans R Soc Lond B Biol Sci* 1999; 354: 739-749.
9. World Health Organization. Status Report on Artemisinin Resistance [Internet]; [cited 2018 Aug 12]. Available from: <http://www.who.int/malaria/publications/atoz/status-rep-artemisinin-resistance-sept2015.pdf>.
10. Noedl H, Se Y, Schaefer K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* 2008; 359: 2619-2620.
11. Asia Pacific Malaria Elimination Network 2014. [Internet]; [cited 2018 Aug 12]. Available from: <http://www.apmen.org>.
12. Phyto AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Striprawat K, Nair S, White MM, Dziekan J, Ling C, Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ, White NJ, Nosten F. Declining efficacy of ar-

- temisinin combination therapy against *P. falciparum* malaria on the Thai-Myanmar border (2003-2013): the role of parasite genetic factors. *Clin Infect Dis* 2016; 63: 784-791.
13. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Ménard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature* 2014; 505: 50-55.
 14. World Health Organization. Status Report on Artemisinin and ACT Resistance [Internet]; [cited 2018 Aug 23]. <https://www.who.int/malaria/publications/atoz/artemisinin-resistance-april2017/en/>.
 15. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med* 2014; 371: 411-423.
 16. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant *Plasmodium falciparum* malaria in vivo is associated with selection of *pfprt* 76T and *pfmdr1* 86Y. *Infect Genet Evol* 2006; 6: 309-314.
 17. Sá JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE. Geographic patterns of *Plasmodium falciparum* drug resistance distinguished by differential responses to amodiaquine and chloroquine. *Proc Natl Acad Sci USA* 2009; 106: 18883-18889.
 18. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in *Plasmodium falciparum*. *Nature* 2000; 403: 906-909.
 19. Sidhu AB, Valderramos SG, Fidock DA. *pfmdr1* mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in *Plasmodium falciparum*. *Mol Microbiol* 2005; 57: 913-926.
 20. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, Krishna S, Gil JP. The role of *pfmdr1* in *Plasmodium falciparum* tolerance to artemether-lumefantrine in Africa. *Trop Med Int Health* 2007; 12: 736-742.
 21. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, Martin RE, Lehane AM, Fidock DA. Globally prevalent *PfMDR1* mutations modulate *Plasmodium falciparum* susceptibility to artemisinin-based combination therapies. *Nat Commun* 2016; 7: 11553.
 22. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. The ABCs of multidrug resistance in malaria. *Trends Parasitol* 2010; 26: 440-446.
 23. Pickard AL, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F, Miller RS, Meshnick SR. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in *pfmdr1*. *Antimicrob Agents Chemother* 2003; 47: 2418-2423.
 24. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Muta-bingwa TK, Sutherland CJ, Hallett RL. Amodiaquine and artemether-lumefantrine select distinct alleles of the *Plasmodium falciparum mdr1* gene in Tanzanian children treated for uncomplicated malaria. *Antimicrob Agents Chemother* 2007; 51: 991-997.
 25. Lekostaj JK, Amoah LE, Roepe PD. A single S1034C mutation confers altered drug sensitivity to *PfMDR1* ATPase activity that is characteristic of the 7G8 isoform. *Mol Biochem Parasitol* 2008; 157: 107-111.
 26. Ministry of Health Malaysia. Health indicators 2014. Malaysia: 2014. Report Number: ISSN 1511-4589 MOH/S/RAN/74.14(TR).
 27. Norahmad NA, Mohd Abd Razak MR, Abdullah NR, Sastu UR, Imwong M, Muniandy PK, Saat MN, Muhammad A, Jelip J, Tikuson M, Yusof N, Rundi C, Mudin RN, Syed Mohamed AF. Prevalence of *Plasmodium falciparum* molecular markers of antimalarial drug resistance in a residual malaria focus area in Sabah, Malaysia. *PLoS One* 2016; 11: e0165515.
 28. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. *Mol Biochem Parasitol* 1993; 61: 315-320.
 29. Basco LK, Ringwald P. Molecular epidemiology of malaria in Cameroon. X. Evaluation of *pfmdr1* mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. *Am J Trop Med Hyg* 2002; 66: 667-671.
 30. Fairhurst RM. Understanding artemisinin-resistant malaria: what a difference a year makes. *Curr Opin Infect Dis* 2015; 28: 417-425.
 31. Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar AH, Kaneko A. Novel mutations in *K13* propeller gene of artemisinin resistant *Plasmodium falciparum*. *Emerg Infect Dis* 2015; 21: 490-492.
 32. Wurtz N, Fall B, Pascual A, Fall M, Baret E, Camara C, Nakoulima A, Diatta B, Fall KB, Mbaye PS, Diémé Y, Bercion R, Wade B, Pradines B. Role of *Pfmdr1* in in vitro *Plasmodium falciparum* susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin. *Antimicrob Agents Chemother* 2014; 58: 7032-7040.
 33. Imwong M SK, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van der Pluijm RW, Tripura R, Miotto O, Menard D, Dhorda M, Day NPJ, White NJ, Dondorp AM. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiol-

- ogy observational study. *Lancet Infect Dis* 2017; 17: 491-497.
34. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dol-ecek C, Hien TT, Boni ME, Thai CQ, Amambua-Ngwa A, Conway DJ, Djimdé AA, Doumbo OK, Zongo I, Ouedraogo JB, Alcock D, Drury E, Auburn S, Koch O, Sanders M, Hubbard C, Maslen G, Ruano-Rubio V, Jyothi D, Miles A, O'Brien J, Gamble C, Oyola SO, Rayner JC, Newbold CI, Berriman M, Spencer CC, McVean G, Day NP, White NJ, Bethell D, Dondorp AM, Plowe CV, Fairhurst RM, Kwiatkowski DP. Multiple populations of artemisinin-resistant *Plasmodium falciparum* in Cambodia. *Nat Genet* 2013; 45: 648-655.
 35. Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, Lim P, Mead D, Oyola SO, Dhorda M, Imwong M, Woodrow C, Manske M, Stalker J, Drury E, Campino S, Amenga-Etego L, Thanh TN, Tran HT, Ringwald P, Bethell D, Nosten F, Phyto AP, Pukrittayakamee S, Chotivanich K, Chuor CM, Nguon C, Suon S, Sreng S, Newton PN, Mayxay M, Khanthavong M, Hongvanthong B, Htut Y, Han KT, Kyaw MP, Faiz MA, Fanello CI, Onyamboko M, Mokuolu OA, Jacob CG, Takala-Harrison S, Plowe CV, Day NP, Dondorp AM, Spencer CC, McVean G, Fairhurst RM, White NJ, Kwiatkowski DP. Genetic architecture of artemisinin-resistant *Plasmodium falciparum*. *Nat Genet* 2015; 47: 226-234.
 36. Kobasa T, Talundzic E, Sug-Aram R, Boondat P, Goldman IE, Lucchi NW, Dharmarak P, Sintasath D, Fukuda M, Whistler T, MacArthur J, Udhayakumar V, Prempre P, Chinanonwait N. Emergence and Spread of *kelch13* Mutations Associated with Artemisinin Resistance in *Plasmodium falciparum* Parasites in 12 Thai Provinces from 2007 to 2016. *Antimicrob Agents Chemother* 2018; 62: e02141-17.
 37. Noedl H, Se Y, Schaefer K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. *N Engl J Med* 2008; 359: 2619-2620.
 38. Ye R, Hu D, Zhang Y, Huang Y, Sun X, Wang J, Chen X, Zhou H, Zhang D, Mungthin M, Pan W. Distinctive origin of artemisinin-resistant *Plasmodium falciparum* on the China-Myanmar border. *Sci Rep* 2016; 6: 20100.
 39. Putapornpit C, Kuamsab N, Kosuwin R, Tantiwattanasub W, Vejakama P, Sueblinvong T, Seethamchai S, Jongwutiwes S, Hughes AL. Natural selection of *K13* mutants of *Plasmodium falciparum* in response to artemisinin combination therapies in Thailand. *Clin Microbiol Infect* 2016; 22: 285. e1-8.
 40. Talundzic E, Okoth SA, Congpuong K, Plucinski MM, Morton L, Goldman IE, Kachur PS, Wongsrichanalai C, Satimai W, Barnwell JW, Udhayakumar V. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. *PLoS Pathog* 2015; 11: e1004789.
 41. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD1 Dieye A, Djallé D, Dorkenoo MA, Eboumbou-Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz ME, Fola AA, Fuehrer HP, Hassan AM, Herrera S, Hongvanthong B, Houzé S, Ibrahim ML, Jahirul-Karim M, Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner PG, Lacerda M, Leang R, Leelawong M, Li M1, Lin K, Mazarati JB, Ménard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K, Nambozi M, Niaré K, Noedl H, Ouédraogo JB, Pillai DR, Pradines B, Quang-Phuc B, Ramharter M, Randri-anarivelosia M, Sattabongkot J, Sheikh-Omar A, Silué KD, Siri-ma SB, Sutherland C, Syafruddin D, Tahar R, Tang LH, Touré OA, Tshibangu-wa-Tshibangu P, Vigan-Womas I, Warsame M, Wini L, Zakeri S, Kim S, Eam R, Berne L, Khean C, Chy S, Ken M, Loch K, Canier L, Duru V, Legrand E, Barale JC, Stokes B, Straimer J, Witkowski B, Fidock DA, Rogier C, Ringwald P, Ariey F, Mercereau-Puijalon O. A Worldwide Map of *Plasmodium falciparum* K13-Propeller Polymorphisms. *N Engl J Med* 2016; 374: 2453-2464.
 42. Imwong M, Jindakhad T, Kunasol C, Sutawong K, Vejakama P, Dondorp AM. An outbreak of artemisinin resistant falciparum malaria in Eastern Thailand. *Sci Rep* 2015; 5: 17412.
 43. Mungthin M, Intanakom S, Suwandittakul N, Suida P, Amsakul S, Sitthichot N, Thammapalo S, Leelayoova S. Distribution of *pfmdr1* polymorphisms in *Plasmodium falciparum* isolated from Southern Thailand. *Malar J* 2014; 13: 117.
 44. Khim N, Bouchier C, Ekala MT, Incardona S, Lim P, Legrand E, Jambou R, Doung S, Puijalon OM, Fandeur T. Countrywide survey shows very high prevalence of *Plasmodium falciparum* multi-locus resistance genotypes in Cambodia. *Antimicrob Agents Chemother* 2005; 49: 3147-3152.
 45. Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, Das D, Phyto AP, Lwin KM, Pukrittayakamee S, Lee SJ, Saisung S, Koecharoen K, Nguon C, Day NP, Socheat D, White NJ. Exploring the contribution of candidate genes to artemisinin resistance in *Plasmodium falciparum*. *Antimicrob Agents Chemother* 2010; 54: 2886-2892.
 46. Mungthin M, Watanatanasup E, Sitthichot N, Suwandittakul N, Khositnithikul R, Ward SA. Influence of the *pfmdr1* gene on in vitro sensitivities of piperazine in Thai isolates of *Plasmodium falciparum*. *Am J Trop Med Hyg* 2017; 96: 624-629.